Roughly 4 million American adults live with fibromyalgia — chronic widespread pain, profound fatigue, unrefreshing sleep, and cognitive fog, in the absence of inflammation or tissue damage. For decades the condition was dismissed as psychological. Modern neuroscience has shown the opposite: the nervous system in fibromyalgia is measurably more sensitive to painful stimuli, and the brain's own pain-inhibitory pathways are less effective. This is the practical map of what is happening and how it is treated.
For much of the twentieth century, fibromyalgia was widely regarded as a psychological condition — a patient's complaint without a physical basis. That view is no longer supported by the evidence. Functional MRI, quantitative sensory testing, and electrophysiology have all converged on a clear finding: the nervous system in fibromyalgia amplifies pain signals, and this amplification is measurable, reproducible, and physiological.
The central concept is central sensitization. Normally, pain is a protective signal that begins with nociceptors — specialized nerve endings in the tissues that fire when exposed to potentially damaging stimuli. Their signal ascends through the dorsal horn of the spinal cord to the brain, where it is processed and interpreted. In the healthy nervous system, this system has a "gain" — a ratio between input and perceived output — that can be adjusted. In fibromyalgia, that gain is set too high. Neurons in the dorsal horn are more excitable, the ascending pain pathways fire more readily, and — critically — the descending pain-inhibitory pathways from the brainstem are less effective. The result is that stimuli which would be mild or unnoticeable for most people are experienced as painful.
Three distinct mechanisms contribute. Increased excitability of dorsal horn neurons — mediated by glutamate, substance P, and NMDA receptor activation — lowers the firing threshold for pain signals. Impaired descending inhibition — involving the periaqueductal gray and rostral ventromedial medulla — means the brain cannot effectively "turn down" ascending pain signals. And glial cell activation — primarily microglia and astrocytes — releases pro-inflammatory cytokines that further sensitize central neurons. These are not psychological processes. They are cellular physiology.
The clinical consequence is that fibromyalgia is not a disease of the joints, muscles, or connective tissue — it is a disease of the pain processing system itself. This is why patients typically have normal inflammatory markers, normal imaging, and normal joint examinations, yet experience pain that is real and disabling. It also explains why medications developed for other purposes — anticonvulsants and antidepressants — are effective in fibromyalgia: they act on the same central mechanisms that are dysregulated. And it explains why the same patient population frequently reports other central sensitization syndromes — IBS, migraine, temporomandibular disorder, chronic pelvic pain, and interstitial cystitis — because the underlying mechanism is shared. A reference on what is Metformin used for illustrates how seemingly unrelated conditions can share common physiological pathways in other body systems.
Normal nociceptor firing from muscles, skin, and joints. No tissue damage required — input is normal.
Glutamate, substance P, and NMDA activation make dorsal horn neurons hyperexcitable. Firing threshold falls.
The brainstem's endogenous analgesia system is less effective. The brain cannot turn down the signal.
Stimuli that should be mild are perceived as intense. Chronic pain without peripheral pathology.
There is no blood test, imaging study, or biopsy that confirms fibromyalgia. The diagnosis is made clinically, based on history and examination, using the 2016 revision of the American College of Rheumatology criteria. This is not a weakness of the diagnosis — it is a reflection of the fact that the disorder is functional and central, not structural and peripheral.
Count of body regions with pain in the past week. 19 possible regions, score 0–19.
Severity of core symptoms over the past week, scored 0–3 each.
SSS total: 0 to 12
Fibromyalgia is not simply "widespread pain." The condition involves several distinct symptom domains, each of which contributes to disability and each of which requires its own therapeutic attention.
Pain in multiple body regions, typically for more than 3 months. Often described as burning, aching, or "like a bad flu." Worse in the morning and after overuse. Not explained by inflammation, joint damage, or muscle pathology.
Reported by 90 percent of patients. Distinct from ordinary tiredness — not relieved by sleep or rest. Interferes with daily activities, work, and social function. Overlaps significantly with chronic fatigue syndrome, and the two conditions frequently coexist.
Waking unrefreshed despite adequate duration. Polysomnography shows alpha-wave intrusion into slow-wave sleep — a pattern that fragments deep sleep. Many patients also have primary sleep disorders (apnea, restless legs) that require separate evaluation.
Commonly called "fibro fog." Difficulty with concentration, memory, and word-finding. Often worse with fatigue, stress, or pain flares. Reflects altered central processing, not early dementia.
Headache, IBS, TMJ pain, pelvic pain, dry eyes, dry mouth, dizziness, and paresthesias. Reflect the same central sensitization in other organ systems. Each may require its own treatment approach in addition to fibromyalgia care.
Three medications are FDA-approved for fibromyalgia in the U.S. — pregabalin, duloxetine, and milnacipran. Several others are used off-label with good supporting evidence. Response is typically modest, and combining medication with non-pharmacologic treatment is essential.
The first medication FDA-approved for fibromyalgia (2007). Binds the α2δ subunit of voltage-gated calcium channels in the spinal cord and brain, reducing release of excitatory neurotransmitters. Reduces pain and improves sleep and fatigue in some patients.
Requires tapering on discontinuation. Common side effects: dizziness, somnolence, weight gain, and peripheral edema. Schedule V controlled substance in the U.S. due to misuse potential. Gabapentin is a related off-label option.
A serotonin-norepinephrine reuptake inhibitor approved for fibromyalgia (2008). Enhances descending pain inhibition by increasing norepinephrine and serotonin in the spinal cord and brainstem. Particularly useful in patients with comorbid depression or anxiety.
Common side effects: nausea, dry mouth, somnolence, and constipation. Requires gradual taper on discontinuation. Do not combine with MAO inhibitors or other serotonergic drugs. Monitor blood pressure.
Approved for fibromyalgia in 2009. A dual serotonin-norepinephrine reuptake inhibitor with relatively greater norepinephrine effect — which may explain its efficacy in pain. Improved pain, fatigue, and physical function in clinical trials.
Twice-daily dosing (unlike duloxetine). Common side effects: nausea, headache, constipation, and palpitations. Requires gradual taper. Monitor blood pressure and heart rate. Not widely stocked — check availability before prescribing.
Long used off-label for fibromyalgia, based on evidence from small randomized trials. At low doses (10–50 mg at bedtime), it reduces pain and improves sleep by blocking norepinephrine and serotonin reuptake, and by anticholinergic and antihistaminergic effects.
Anticholinergic side effects — dry mouth, constipation, urinary retention, cognitive effects — limit tolerability in older adults. Cardiotoxic in overdose. Cyclobenzaprine (a related muscle relaxant) is a similar option.
Not effective in fibromyalgia. Opioids act on peripheral and spinal μ-opioid receptors but do not address the central sensitization mechanism — and chronic opioid use is associated with opioid-induced hyperalgesia, which can worsen central pain over time.
NSAIDs target prostaglandin-mediated inflammation, which is absent in fibromyalgia. Neither opioids nor NSAIDs should be used as primary therapy for fibromyalgia. Limited evidence supports their use even as adjuncts.
Medication alone is rarely sufficient for fibromyalgia. The strongest evidence base supports three non-pharmacologic interventions, which should be part of every treatment plan: exercise, cognitive behavioral therapy, and patient education. These are not adjuncts — they are core treatment.
The most consistently effective intervention. Low-intensity aerobic exercise (walking, swimming, cycling) and strength training reduce pain and improve function. Start low and progress slowly — overexertion can trigger flares. Consistency matters more than intensity. Aquatic exercise is particularly well-tolerated.
Target: 20–30 minutes of moderate activity, 2–3 times per week, building gradually. Warm-up and cool-down reduce flare risk.
Strong evidence for reducing pain-related disability and improving mood. CBT addresses the thoughts, behaviors, and emotional responses that amplify the experience of chronic pain — catastrophic thinking, avoidance, and activity-rest cycles. Not "psychological treatment" — it is a treatment for the physiological maintenance of central sensitization.
Also effective: acceptance and commitment therapy (ACT), mindfulness-based stress reduction, and pain neuroscience education.
Understanding that fibromyalgia is a real, biological condition — not a psychological failing — reduces distress and improves outcomes. Pain neuroscience education teaches patients how the nervous system works and why pain can persist without tissue damage.
Includes: sleep hygiene, pacing strategies, stress management, and managing coexisting conditions. A therapeutic relationship with a knowledgeable clinician is itself part of treatment.
Duloxetine and milnacipran increase serotonin. Combining with MAO inhibitors, triptans, tramadol, or other serotonergic drugs can cause serotonin syndrome — agitation, tremor, hyperthermia, clonus. Rare but potentially life-threatening.
Pregabalin, duloxetine, and milnacipran all require gradual discontinuation. Abrupt cessation can cause withdrawal symptoms — anxiety, insomnia, nausea, dizziness, and in some cases increased pain. Do not stop without medical guidance.
SNRIs can increase blood pressure and heart rate. Monitor in patients with hypertension or cardiovascular disease. Blood pressure should be checked at baseline and periodically on duloxetine or milnacipran.
Pregabalin, gabapentin, amitriptyline, and cyclobenzaprine are sedating. Fall risk increases in older adults and in patients on multiple sedating medications. Avoid combining when possible and counsel on caution with driving.
Up to 70 percent of fibromyalgia patients have a primary sleep disorder — especially obstructive sleep apnea. Treating the sleep disorder can substantially improve fibromyalgia symptoms. A sleep study should be considered if snoring or daytime sleepiness is present.
Pregabalin and gabapentin interact with opioids (respiratory depression), benzodiazepines, and alcohol. Duloxetine interacts with other serotonergic drugs and with CYP1A2 and CYP2D6 substrates. Give every prescriber and pharmacist a complete medication list — a reference on Metformin brand vs generic illustrates the same principle of careful medication review.
Fibromyalgia is a diagnosis of inclusion, not exclusion — but several conditions can present similarly and require specific treatment. Before confirming fibromyalgia, a clinician should consider these.
Pregabalin, duloxetine, and amitriptyline are all available as generics in the U.S., often on $4 to $30 per month lists at major pharmacies. Milnacipran (Savella) remains brand-only and significantly more expensive — often $300 or more per month — and is not widely stocked. Because pregabalin and duloxetine are generic and effective, they are usually the preferred first choices when cost matters. A live comparison across licensed U.S. sellers, like the one shown for how to manage type 2 diabetes, illustrates the same pricing dynamics that apply to any chronic medication.
Non-pharmacologic treatment — graded exercise and CBT — is often the most effective intervention and the least expensive. Physical therapy is covered by most insurance plans with a physician referral. CBT is covered by most plans as mental health care. Many fibromyalgia patients find that a combination of a structured exercise program and CBT produces better results than medication alone, and at lower long-term cost.
Sleep disorder screening can be essential. If obstructive sleep apnea is present, treating it often improves fibromyalgia symptoms significantly. Sleep studies are covered by Medicare and most commercial plans when medically indicated.
For patients on multiple chronic medications — which is common in fibromyalgia, given the frequent coexistence of depression, migraine, IBS, and other conditions — pharmacy-level pricing on generics adds up. The same medication can cost meaningfully more at one licensed pharmacy than another, and a short comparison before each refill is a useful habit. A resource like this on buy Metformin online is a starting point for patients new to comparing sellers across pharmacies.
Pregabalin, duloxetine, and amitriptyline are all generic and affordable — but prices still vary meaningfully between pharmacies, and for patients managing multiple conditions, the total monthly cost adds up. A short comparison across licensed U.S. sellers before each refill is a useful habit, and it is the same approach that resources like buy Metformin online apply to widely prescribed medications.
Open the price comparison